Sökning: onr:"swepub:oai:DiVA.org:uu-307551" > Lenalidomide-bendam...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04540naa a2200481 4500 | |
001 | oai:DiVA.org:uu-307551 | |
003 | SwePub | |
008 | 161117s2016 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3075512 URI |
024 | 7 | a https://doi.org/10.1182/blood-2016-03-7040232 DOI |
040 | a (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Albertsson-Lindblad, Alexandrau Skane Univ Hosp, Dept Oncol, SE-22185 Lund, Sweden.4 aut |
245 | 1 0 | a Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma |
264 | 1 | b American Society of Hematology,c 2016 |
338 | a print2 rdacarrier | |
520 | a For elderly patients with mantle cell lymphoma (MCL), there is no defined standard therapy. In this multicenter, open-label phase 1/2 trial, we evaluated the addition of lenalidomide (LEN) to rituximab-bendamustine (R-B) as first-line treatment for elderly patients with MCL. Patients >65 years with untreated MCL, stages II-IV were eligible for inclusion. Primary end points were maximally tolerable dose (MTD) of LEN and progression-free survival (PFS). Patients received 6 cycles every four weeks of L-B-R (L D1-14, B 90 mg/m(2) IV, days 1-2 and R 375 mg/m(2) IV, day 1) followed by single LEN (days 1-21, every four weeks, cycles 7-13). Fifty-one patients (median age 71 years) were enrolled from 2009 to 2013. In phase 1, the MTD of LEN was defined as 10 mg in cycles 2 through 6, and omitted in cycle 1. After 6 cycles, the complete remission rate (CRR) was 64%, and 36% were MRD negative. At a median follow-up time of 31 months, median PFS was 42 months and 3-year overall survival was 73%. Infection was the most common nonhematologic grade 3 to 5 event and occurred in 21 (42%) patients. Opportunistic infections occurred in 3 patients: 2 Pneumocystis carinii pneumonia and 1 cytomegalovirus retinitis. Second primary malignancies (SPM) were observed in 8 patients (16%). LEN could safely be combined with R-B when added from the second cycle in patients with MCL, and was associated with a high rate of CR and molecular remission. However, we observed a high degree of severe infections and an unexpected high number of SPMs, which may limit its use. This trial is registered at www.Clinicaltrials.gov as #NCT00963534. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Klinisk laboratoriemedicin0 (SwePub)302232 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Clinical Laboratory Medicine0 (SwePub)302232 hsv//eng |
653 | a Patologi | |
653 | a Pathology | |
700 | 1 | a Kolstad, Arneu Oslo Univ Hosp, Dept Oncol, Oslo, Norway.4 aut |
700 | 1 | a Laurell, Annau Univ Uppsala Hosp, Dept Oncol, Uppsala, Sweden.4 aut0 (Swepub:uu)annajohn |
700 | 1 | a Raty, Riikkau Helsinki Univ Hosp, Dept Hematol, Helsinki, Finland.4 aut |
700 | 1 | a Gronbaek, Kirstenu Rigshosp, Dept Hematol, Copenhagen, Denmark.4 aut |
700 | 1 | a Sundberg, Janu Skane Univ Hosp, Dept Oncol, SE-22185 Lund, Sweden.4 aut |
700 | 1 | a Pedersen, Lone Bredou Rigshosp, Dept Hematol, Copenhagen, Denmark.4 aut |
700 | 1 | a Ralfkiaer, Elisabethu Rigshosp, Dept Pathol, Copenhagen, Denmark.4 aut |
700 | 1 | a Karjalainen-Lindsberg, Marja-Liisau Univ Helsinki, Cent Hosp, Dept Pathol, Helsinki, Finland.4 aut |
700 | 1 | a Sundström, Christeru Uppsala universitet,Klinisk och experimentell patologi,Department of Pathology, Uppsala University Hospital, Uppsala, Sweden; and.,Rose-Marie Amini4 aut0 (Swepub:uu)chrisund |
700 | 1 | a Ehinger, Matsu Univ Lund Hosp, Dept Pathol Cytol, Lund, Sweden.4 aut |
700 | 1 | a Geisler, Christianu Rigshosp, Dept Hematol, Copenhagen, Denmark.4 aut |
700 | 1 | a Jerkeman, Matsu Skane Univ Hosp, Dept Oncol, SE-22185 Lund, Sweden.4 aut |
710 | 2 | a Skane Univ Hosp, Dept Oncol, SE-22185 Lund, Sweden.b Oslo Univ Hosp, Dept Oncol, Oslo, Norway.4 org |
773 | 0 | t Bloodd : American Society of Hematologyg 128:14, s. 1814-1820q 128:14<1814-1820x 0006-4971x 1528-0020 |
856 | 4 | u https://ashpublications.org/blood/article-pdf/128/14/1814/1396178/1814.pdf |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-307551 |
856 | 4 8 | u https://doi.org/10.1182/blood-2016-03-704023 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy